Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling
暂无分享,去创建一个
Kazunori Kataoka | Nobuhiro Nishiyama | Kohei Miyazono | Mitsunobu R Kano | Y. Ouchi | K. Miyazono | M. Kano | N. Nishiyama | K. Kataoka | M. Kaminishi | Kunihiko Kiyono | M. Yashiro | K. Hirakawa | Y. Bae | Y. Morishita | Younsoo Bae | Kunihiko Kiyono | Yasuyuki Morishita | Masakazu Yashiro | Yasuyoshi Ouchi | C. Iwata | Masako Oka | T. Fujii | A. Komuro | Michio Kaminishi | Kosei Hirakawa | Caname Iwata | Masako Oka | Tomoko Fujii | Akiyoshi Komuro | K. Kiyono
[1] Ruth Duncan,et al. Polymer conjugates as anticancer nanomedicines , 2006, Nature Reviews Cancer.
[2] Xiu-fen Lei,et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. , 2006, Cancer research.
[3] F. Blanco,et al. Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway. , 2006, Clinical medicine & research.
[4] M. Dewhirst,et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. , 2006, Journal of the National Cancer Institute.
[5] R. Derynck,et al. SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS , 2005 .
[6] Y. Ouchi,et al. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B–PDGFRβ signaling , 2005, Journal of Cell Science.
[7] Fuminori Moriyasu,et al. Differential diagnosis of pancreatic tumors using ultrasound contrast imaging , 2005, Journal of Gastroenterology.
[8] K. Kataoka,et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel , 2005, British Journal of Cancer.
[9] M. Ferrari. Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.
[10] P. Dijke,et al. TGF-h receptor function in the endothelium , 2005 .
[11] Kazunori Kataoka,et al. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. , 2005, Bioconjugate chemistry.
[12] Jonathan M. Yingling,et al. Development of TGF-β signalling inhibitors for cancer therapy , 2004, Nature Reviews Drug Discovery.
[13] A H Gandjbakhche,et al. Quantitative Assessment of Tumor Vasculature and Response to Therapy in Kaposi's Sarcoma Using Functional Noninvasive Imaging , 2004, Technology in cancer research & treatment.
[14] M. Mackenzie. Molecular therapy in pancreatic adenocarcinoma. , 2004, The Lancet. Oncology.
[15] M. Yashiro,et al. Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice , 2004, Clinical & Experimental Metastasis.
[16] S. Nishikawa,et al. TGF-β receptor kinase inhibitor enhances growth and integrity of embryonic stem cell–derived endothelial cells , 2003, The Journal of cell biology.
[17] Y. Sugiyama,et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. , 2003, Cancer research.
[18] M. Vieth,et al. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. , 2003, Journal of medicinal chemistry.
[19] L. Wakefield,et al. The two faces of transforming growth factor β in carcinogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[20] P. Choyke,et al. Imaging of angiogenesis: from microscope to clinic , 2003, Nature Medicine.
[21] D. Tzemach,et al. Dose Dependency of Pharmacokinetics and Therapeutic Efficacy of Pegylated Liposomal Doxorubicin (DOXIL) in Murine Models , 2002, Journal of drug targeting.
[22] M. Goumans,et al. Abnormal angiogenesis but intact hematopoietic potential in TGF‐β type I receptor‐deficient mice , 2001, The EMBO journal.
[23] K. Kataoka,et al. Block copolymer micelles for drug delivery: design, characterization and biological significance. , 2001, Advanced drug delivery reviews.
[24] F. Muggia,et al. Liposomal encapsulated anthracyclines: new therapeutic horizons , 2001, Current oncology reports.
[25] Dean Y. Li,et al. Arteriovenous malformations in mice lacking activin receptor-like kinase-1 , 2000, Nature Genetics.
[26] P. Donahoe,et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[27] D. Marchuk,et al. Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. , 2000, Developmental biology.
[28] B. Brooke,et al. Defective angiogenesis in mice lacking endoglin. , 1999, Science.
[29] T. Kawarabayashi,et al. The blood flow characteristics in borderline ovarian tumors based on both color Doppler ultrasound and histopathological analyses. , 1998, Gynecologic oncology.
[30] K. Hirschi,et al. PDGF, TGF-β, and Heterotypic Cell–Cell Interactions Mediate Endothelial Cell–induced Recruitment of 10T1/2 Cells and Their Differentiation to a Smooth Muscle Fate , 1998, The Journal of cell biology.
[31] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] N. Tsuji,et al. Endogenous tumor necrosis factor inhibits the cytotoxicity of exogenous tumor necrosis factor and adriamycin in pancreatic carcinoma cells. , 1996, Pancreas.
[33] L. Ellis,et al. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] H. Maeda,et al. Tumoritropic and lymphotropic principles of macromolecular drugs. , 1989, Critical reviews in therapeutic drug carrier systems.
[35] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.